EMA backs restrictions on certain immune-regulating drugs
Once the European Commission signs off, use of several so-called JAK inhibitors sold by Eli Lilly, Pfizer and other drugmakers will be limited among smokers and patients who are at high risk of certain health complications.
"The EMA’s Committee for Medicinal Products for Human Use endorsed a recent recommendation from the agency’s safety panel to restrict use of so-called JAK inhibitors in patients who are at least 65 years old, at increased risk of major heart disease or cancer, or are active or long-time smokers. Those drugs should only be used if “no suitable treatment alternatives are available,” the committee said."
